JP2018525405A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018525405A5 JP2018525405A5 JP2018509597A JP2018509597A JP2018525405A5 JP 2018525405 A5 JP2018525405 A5 JP 2018525405A5 JP 2018509597 A JP2018509597 A JP 2018509597A JP 2018509597 A JP2018509597 A JP 2018509597A JP 2018525405 A5 JP2018525405 A5 JP 2018525405A5
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- cancer
- solvate
- alkyl
- salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 18
- 125000000217 alkyl group Chemical group 0.000 claims 17
- 150000003839 salts Chemical class 0.000 claims 17
- 239000012453 solvate Substances 0.000 claims 17
- 229910052760 oxygen Inorganic materials 0.000 claims 12
- 229910052717 sulfur Inorganic materials 0.000 claims 11
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 9
- -1 N-methylpyrrolyl Chemical group 0.000 claims 8
- 229910052799 carbon Inorganic materials 0.000 claims 8
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 8
- 229910052739 hydrogen Inorganic materials 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 4
- 125000001424 substituent group Chemical group 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 125000001072 heteroaryl group Chemical group 0.000 claims 3
- 125000002883 imidazolyl group Chemical group 0.000 claims 3
- 230000002062 proliferating effect Effects 0.000 claims 3
- 125000000168 pyrrolyl group Chemical group 0.000 claims 3
- DYSJMQABFPKAQM-UHFFFAOYSA-M 1-benzothiophene-2-carboxylate Chemical compound C1=CC=C2SC(C(=O)[O-])=CC2=C1 DYSJMQABFPKAQM-UHFFFAOYSA-M 0.000 claims 2
- XVXVLZDETLWGNP-DEOSSOPVSA-N 4-[6-[[(6aS)-2-methoxy-12-oxo-7,8,9,10-tetrahydro-6aH-pyrido[2,1-c][1,4]benzodiazepin-3-yl]oxy]hexanoylamino]-N-(4-aminophenyl)-1-methylpyrrole-2-carboxamide Chemical compound COc1cc2c(cc1OCCCCCC(=O)Nc1cc(C(=O)Nc3ccc(N)cc3)n(C)c1)N=C[C@@H]1CCCCN1C2=O XVXVLZDETLWGNP-DEOSSOPVSA-N 0.000 claims 2
- 125000002947 alkylene group Chemical group 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 125000003710 aryl alkyl group Chemical group 0.000 claims 2
- DNSISZSEWVHGLH-UHFFFAOYSA-N butanamide Chemical compound CCCC(N)=O DNSISZSEWVHGLH-UHFFFAOYSA-N 0.000 claims 2
- 125000004432 carbon atom Chemical group C* 0.000 claims 2
- UKJLNMAFNRKWGR-UHFFFAOYSA-N cyclohexatrienamine Chemical group NC1=CC=C=C[CH]1 UKJLNMAFNRKWGR-UHFFFAOYSA-N 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims 2
- MGWDHUSBGIEYPV-LJAQVGFWSA-N methyl 4-[4-[[4-[4-[[(6aS)-2-methoxy-12-oxo-7,8,9,10-tetrahydro-6aH-pyrido[2,1-c][1,4]benzodiazepin-3-yl]oxy]butanoylamino]benzoyl]amino]phenyl]-1-methylpyrrole-2-carboxylate Chemical compound COC(=O)c1cc(cn1C)-c1ccc(NC(=O)c2ccc(NC(=O)CCCOc3cc4N=C[C@@H]5CCCCN5C(=O)c4cc3OC)cc2)cc1 MGWDHUSBGIEYPV-LJAQVGFWSA-N 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010005949 Bone cancer Diseases 0.000 claims 1
- 208000018084 Bone neoplasm Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical group O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 claims 1
- 208000005016 Intestinal Neoplasms Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 208000003445 Mouth Neoplasms Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 239000002202 Polyethylene glycol Substances 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 201000000582 Retinoblastoma Diseases 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 1
- 206010057644 Testis cancer Diseases 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 claims 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 claims 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 claims 1
- 239000011203 carbon fibre reinforced carbon Substances 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 125000002541 furyl group Chemical group 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 125000003827 glycol group Chemical group 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 125000005549 heteroarylene group Chemical group 0.000 claims 1
- 125000001041 indolyl group Chemical group 0.000 claims 1
- 201000002313 intestinal cancer Diseases 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 125000002971 oxazolyl group Chemical group 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 206010038038 rectal cancer Diseases 0.000 claims 1
- 201000001275 rectum cancer Diseases 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 230000008685 targeting Effects 0.000 claims 1
- 201000003120 testicular cancer Diseases 0.000 claims 1
- 125000000335 thiazolyl group Chemical group 0.000 claims 1
- 125000001544 thienyl group Chemical group 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 206010046766 uterine cancer Diseases 0.000 claims 1
- 0 C[n]1c(C(OC)=O)cc(-c(cc2)ccc2NC(c2nc(NC(CCCOc(c(O**)c3)cc(N=CC4N5CCCCC4)c3C5=O)=O)c[n]2C)=O)c1 Chemical compound C[n]1c(C(OC)=O)cc(-c(cc2)ccc2NC(c2nc(NC(CCCOc(c(O**)c3)cc(N=CC4N5CCCCC4)c3C5=O)=O)c[n]2C)=O)c1 0.000 description 3
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021103836A JP2021152063A (ja) | 2015-08-21 | 2021-06-23 | 抗増殖活性を有するピペリジノベンゾジアゼピン化合物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1514928.9A GB201514928D0 (en) | 2015-08-21 | 2015-08-21 | PDD compounds |
| GB1514928.9 | 2015-08-21 | ||
| PCT/GB2016/052565 WO2017032983A1 (en) | 2015-08-21 | 2016-08-19 | Piperidinobenzodiazepine compounds with anti proliferative activity |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021103836A Division JP2021152063A (ja) | 2015-08-21 | 2021-06-23 | 抗増殖活性を有するピペリジノベンゾジアゼピン化合物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018525405A JP2018525405A (ja) | 2018-09-06 |
| JP2018525405A5 true JP2018525405A5 (enExample) | 2019-09-26 |
| JP6903635B2 JP6903635B2 (ja) | 2021-07-14 |
Family
ID=54292043
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018509597A Active JP6903635B2 (ja) | 2015-08-21 | 2016-08-19 | 抗増殖活性を有するピペリジノベンゾジアゼピン化合物 |
| JP2021103836A Ceased JP2021152063A (ja) | 2015-08-21 | 2021-06-23 | 抗増殖活性を有するピペリジノベンゾジアゼピン化合物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021103836A Ceased JP2021152063A (ja) | 2015-08-21 | 2021-06-23 | 抗増殖活性を有するピペリジノベンゾジアゼピン化合物 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US10975072B2 (enExample) |
| EP (2) | EP4086251A1 (enExample) |
| JP (2) | JP6903635B2 (enExample) |
| KR (1) | KR102710425B1 (enExample) |
| CN (2) | CN108602803A (enExample) |
| AU (1) | AU2016313228B2 (enExample) |
| CA (1) | CA2996406A1 (enExample) |
| DK (1) | DK3337795T3 (enExample) |
| EA (1) | EA201890539A1 (enExample) |
| GB (1) | GB201514928D0 (enExample) |
| IL (1) | IL257650B (enExample) |
| MX (1) | MX395406B (enExample) |
| WO (1) | WO2017032983A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201510010D0 (en) | 2015-06-09 | 2015-07-22 | King S College London | PDD and BPD compounds |
| GB201514928D0 (en) * | 2015-08-21 | 2015-10-07 | King S College London | PDD compounds |
| US20180339985A1 (en) * | 2015-08-21 | 2018-11-29 | Femtogenix Limited | Pdd compounds |
| WO2017201132A2 (en) | 2016-05-18 | 2017-11-23 | Mersana Therapeutics, Inc. | Pyrrolobenzodiazepines and conjugates thereof |
| US10526294B2 (en) | 2016-06-24 | 2020-01-07 | Mersana Therapeutics, Inc. | Pyrrolobenzodiazepines and conjugates thereof |
| US11638760B2 (en) | 2017-11-27 | 2023-05-02 | Mersana Therapeutics, Inc. | Pyrrolobenzodiazepine antibody conjugates |
| GB201814281D0 (en) * | 2018-09-03 | 2018-10-17 | Femtogenix Ltd | Cytotoxic agents |
| GB2597532A (en) | 2020-07-28 | 2022-02-02 | Femtogenix Ltd | Cytotoxic compounds |
| AU2023298568A1 (en) | 2022-06-30 | 2025-01-09 | Toray Industries, Inc. | Pharmaceutical composition for cancer treatment and/or prevention |
| WO2024127333A1 (en) * | 2022-12-14 | 2024-06-20 | Pheon Therapeutics Ltd | Cytotoxic compounds |
| AU2023393382A1 (en) | 2022-12-14 | 2025-06-19 | Pheon Therapeutics Ltd | Cytotoxic compounds |
| WO2025262641A1 (en) | 2024-06-19 | 2025-12-26 | Pheon Therapeutics Ltd | Antibody drug conjugates that bind cdcp1 and uses thereof |
Family Cites Families (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5841878A (ja) * | 1981-09-07 | 1983-03-11 | Fujisawa Pharmaceut Co Ltd | ベンゾジアゼピン誘導体、その製法およびそれを有効成分として含有する抗がん剤 |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5366972A (en) | 1989-04-20 | 1994-11-22 | Boehringer Ingelheim Pharmaceuticals, Inc. | 5,11-dihydro-6H-dipyrido(3,2-B:2',3'-E)(1,4)diazepines and their use in the prevention or treatment of HIV infection |
| US5418229A (en) | 1990-01-06 | 1995-05-23 | Alker; David | Muscarinic receptor antagonists |
| WO1993013777A1 (en) | 1992-01-21 | 1993-07-22 | Merck & Co., Inc. | Method of using m1-selective antimuscarinic pyridobenzodiazepinones in axial myopia therapy |
| WO1994022861A1 (en) | 1993-04-05 | 1994-10-13 | Pharmaceutical Discovery Corporation | PYRIDO[2,3-b][1,4]BENZODIAZEPINONES AS M2 RECEPTOR LIGAND FOR THE TREATMENT OF NEUROLOGICAL DISORDERS |
| AU5844796A (en) | 1995-05-31 | 1996-12-18 | Yamanouchi Pharmaceutical Co., Ltd. | Fused benzodiazepinone derivatives and medicinal composition of the same |
| US5650409A (en) | 1995-06-02 | 1997-07-22 | Cortex Pharmaceuticals, Inc. | Benzoyl piperidines/pyrrolidines for enhancing synaptic response |
| AU758160B2 (en) | 1997-08-22 | 2003-03-20 | Kaken Pharmaceutical Co., Ltd. | Novel amide derivatives |
| ES2260570T3 (es) | 1998-08-27 | 2006-11-01 | Spirogen Limited | Pirrolobenziodiazepinas dimericas. |
| US6608193B2 (en) | 2001-12-21 | 2003-08-19 | The Procter & Gamble Company | Methods for synthesis of amino-tetrahydroisoquinoline ring compounds |
| ES2285227T3 (es) | 2002-08-05 | 2007-11-16 | Eli Lilly And Company | Arilbenzodiazepinas sustituidas con piperazina. |
| GB0226593D0 (en) | 2002-11-14 | 2002-12-24 | Consultants Ltd | Compounds |
| US7456169B2 (en) | 2003-02-27 | 2008-11-25 | Abbott Laboratories Inc. | Heterocyclic kinase inhibitors |
| CA2520901C (en) | 2003-03-31 | 2009-09-08 | Council Of Scientific And Industrial Research | Pyrene-linked pyrrolo (2,1-c) (1,4) benzodiazepine derivatives useful as anticancer agents |
| GB0308335D0 (en) | 2003-04-10 | 2003-05-14 | Novartis Ag | Organic compounds |
| GB0404578D0 (en) | 2004-03-01 | 2004-04-07 | Spirogen Ltd | Pyrrolobenzodiazepines |
| WO2005117876A1 (en) | 2004-06-01 | 2005-12-15 | University Of Virginia Patent Foundation | Dual small molecule inhibitors of cancer and angiogenesis |
| EP1781300A1 (en) | 2004-07-16 | 2007-05-09 | ProteoSys AG | Muscarinic antagonists with parp and sir modulatng activity as agents for inflammatory diseases |
| TR201808537T4 (tr) | 2004-09-23 | 2018-07-23 | Genentech Inc | Sistein değiştirilmiş antikorlar ve konjugatlar. |
| IT1362675B (it) | 2005-03-15 | 2009-06-25 | Menarini Internat Operations Luxembourg Sa | N-idrossiammidi -sostituiti con gruppi triciclici come inibitori dell'istone deacelitasi,loro preparazione ed impiego in formulazioni farmaceutiche |
| DE602006006199D1 (de) | 2005-10-05 | 2009-05-20 | Spirogen Ltd | 4-ä4-(5-oxo-2,3,5,11a-tetrahydro-5h-pyrrolo ä2, 1-cüä1,4übenzodiazepin-8-yloxy)-butyrylaminoü-1h-pyrrol-2-carbonsäurealkylesterderivate und verwandte verbindung zur behandlung einer proliferativen erkrankung |
| WO2008007661A1 (en) | 2006-07-11 | 2008-01-17 | Takeda Pharmaceutical Company Limited | Tricyclic heterocyclic compound and use thereof |
| WO2008020455A2 (en) * | 2006-08-14 | 2008-02-21 | Council Of Scientific & Industrial Research | Pyrrolo[2,1-c][1,4]benzodiazepine hybrids and a process for the preparation thereof |
| PE20090245A1 (es) | 2007-05-08 | 2009-03-17 | Genentech Inc | Anticuerpos anti-muc16 disenados con cisteina y conjugados de anticuerpos y farmacos |
| BRPI0818780A2 (pt) | 2007-10-19 | 2015-04-22 | Genentech Inc | Anticorpo anti-tenb2 planejados por cisteína e conjugados de medicamento com anticorpos |
| JP2009263283A (ja) | 2008-04-25 | 2009-11-12 | Toray Ind Inc | Ｃ型肝炎ウイルス阻害剤 |
| CN102124000B (zh) | 2008-06-17 | 2014-09-17 | 阿斯利康(瑞典)有限公司 | 吡啶化合物 |
| GB0819095D0 (en) | 2008-10-17 | 2008-11-26 | Spirogen Ltd | Pyrrolobenzodiazepines |
| US20110263574A1 (en) | 2009-01-13 | 2011-10-27 | Proteosys Ag | Pirenzepine as otoprotective agent |
| CA3014224C (en) * | 2009-02-05 | 2022-05-24 | Immunogen, Inc. | Condensed benzodiazepine-indoline derivatives and processes to prepare said derivatives |
| EP2421870B1 (en) | 2009-04-23 | 2016-03-09 | AbbVie Inc. | Modulators of 5-ht receptors and methods of use thereof |
| DE102009033392A1 (de) | 2009-07-16 | 2011-01-20 | Merck Patent Gmbh | Heterocyclische Verbindungen als Autotaxin-Inhibitoren II |
| CU20090172A7 (es) | 2009-10-09 | 2011-10-05 | Ct De Investigación Y Desarrollo De Medicamentos | Sistemas tricíclicos y tetracíclicos con actividad sobre el sistema nervioso central y vascular |
| EP2550275B1 (en) | 2010-03-22 | 2014-03-12 | Council Of Scientific & Industrial Research | Pyrrolo[2,1-c][1,4]benzodiazepine-benzothiazole or benzoxazole conjugates linked through piperazine moiety and process for the preparation thereof |
| US20130210804A1 (en) | 2010-10-25 | 2013-08-15 | Neville J. Anthony | Tricyclic mglur5 receptor modulators |
| SI2675480T1 (sl) | 2011-02-15 | 2019-05-31 | Immunogen, Inc. | Metode priprave konjugatov |
| US9006233B2 (en) | 2011-04-28 | 2015-04-14 | Uwm Research Foundation, Inc. | Gabaergic receptor subtype selective ligands and their uses |
| IN2014MN02092A (enExample) * | 2012-04-30 | 2015-09-04 | Spirogen Sarl | |
| WO2015028850A1 (en) * | 2013-09-02 | 2015-03-05 | Hangzhou Dac Biotech Co., Ltd | Novel cytotoxic agents for conjugation of drugs to cell binding molecule |
| AR098743A1 (es) | 2013-12-13 | 2016-06-08 | Genentech Inc | Anticuerpos e inmunoconjugados anti-cd33 |
| GB201407816D0 (en) | 2014-05-02 | 2014-06-18 | King S College London | Pyrrolobenzodiazepine Compounds |
| SI3191135T1 (sl) | 2014-09-12 | 2021-01-29 | Genentech, Inc. | Anti-HER2 protitelesa in imunokonjugati |
| CA2968464A1 (en) | 2014-11-25 | 2016-06-02 | Bayer Pharma Aktiengesellschaft | Substituted pyridobenzodiazepinone-derivatives and use thereof |
| WO2016089830A1 (en) | 2014-12-05 | 2016-06-09 | Merck Sharp & Dohme Corp. | Novel tricyclic compounds as inhibitors of mutant idh enzymes |
| US10442819B2 (en) | 2014-12-05 | 2019-10-15 | Merck Sharp & Dohme Corp. | Tricyclic compounds as inhibitors of mutant IDH enzymes |
| CN107231804B (zh) | 2015-01-14 | 2019-11-26 | 百时美施贵宝公司 | 亚杂芳基桥连苯并二氮杂*二聚体、其缀合物及制备和使用方法 |
| US9504694B2 (en) | 2015-03-19 | 2016-11-29 | Cellerant Therapeutics, Inc. | Isoquinolidinobenzodiazepines |
| GB201510010D0 (en) * | 2015-06-09 | 2015-07-22 | King S College London | PDD and BPD compounds |
| GB201514928D0 (en) * | 2015-08-21 | 2015-10-07 | King S College London | PDD compounds |
| WO2017074914A1 (en) | 2015-10-29 | 2017-05-04 | Merck Sharp & Dohme Corp. | Novel tricyclic compounds as inhibitors of mutant idh enzymes |
| WO2017201132A2 (en) | 2016-05-18 | 2017-11-23 | Mersana Therapeutics, Inc. | Pyrrolobenzodiazepines and conjugates thereof |
| US10526294B2 (en) | 2016-06-24 | 2020-01-07 | Mersana Therapeutics, Inc. | Pyrrolobenzodiazepines and conjugates thereof |
| WO2018053552A2 (en) | 2016-09-19 | 2018-03-22 | Cellerant Therapeutics, Inc. | Isoquinolidinobenzodiazepines |
| US10398783B2 (en) | 2016-10-20 | 2019-09-03 | Bristol-Myers Squibb Company | Antiproliferative compounds and conjugates made therefrom |
-
2015
- 2015-08-21 GB GBGB1514928.9A patent/GB201514928D0/en not_active Ceased
-
2016
- 2016-08-19 AU AU2016313228A patent/AU2016313228B2/en active Active
- 2016-08-19 CN CN201680060201.8A patent/CN108602803A/zh active Pending
- 2016-08-19 MX MX2018002242A patent/MX395406B/es unknown
- 2016-08-19 KR KR1020187007849A patent/KR102710425B1/ko active Active
- 2016-08-19 JP JP2018509597A patent/JP6903635B2/ja active Active
- 2016-08-19 EP EP22178645.2A patent/EP4086251A1/en not_active Withdrawn
- 2016-08-19 EP EP16756759.3A patent/EP3337795B1/en active Active
- 2016-08-19 DK DK16756759.3T patent/DK3337795T3/da active
- 2016-08-19 CN CN202210543524.XA patent/CN114907345B/zh active Active
- 2016-08-19 CA CA2996406A patent/CA2996406A1/en not_active Abandoned
- 2016-08-19 WO PCT/GB2016/052565 patent/WO2017032983A1/en not_active Ceased
- 2016-08-19 EA EA201890539A patent/EA201890539A1/ru unknown
-
2018
- 2018-02-21 US US15/901,714 patent/US10975072B2/en active Active
- 2018-02-21 IL IL257650A patent/IL257650B/en unknown
-
2021
- 2021-06-23 JP JP2021103836A patent/JP2021152063A/ja not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021152063A5 (enExample) | ||
| JP2023515235A5 (enExample) | ||
| ES2670864T3 (es) | Inhibidores de histonas desmetilasas | |
| ES2687985T3 (es) | Combinación de regorafenib y ácido acetilsalicílico para el tratamiento del cáncer colorrectal | |
| HRP20201681T1 (hr) | Inhibitor aurora a kinaze | |
| JP2016505586A5 (enExample) | ||
| CN102149703B (zh) | 抗癌药物及将其用于治疗转移性恶性黑色素瘤及其他癌症 | |
| JP2013534922A5 (enExample) | ||
| JP2009500424A5 (enExample) | ||
| HRP20161498T1 (hr) | Inhibitori kinaza i njihova upotreba u liječenju raka | |
| JP2015511609A5 (enExample) | ||
| JP2019512474A5 (enExample) | ||
| WO2020113213A3 (en) | Cyclic pantetheine derivatives and uses thereof | |
| WO2016050210A1 (zh) | 一种多官能化聚乙二醇衍生物及其制备方法 | |
| JP2019514884A5 (enExample) | ||
| AR056186A1 (es) | Compuesto de imidazo[1,2-a]piridinilo, su uso para la fabricacion de un medicamento y formulacion farmaceutica que lo comprende | |
| JP2014508804A5 (enExample) | ||
| RU2007109073A (ru) | Ингибиторы для атф-зависимого фермента на основе тиазола | |
| HRP20140975T1 (hr) | Derivati n-(3-amino-hinoksalin-2-il)-sulfonamida i njihova uporaba kao inhibitora fosfatidilinozitol 3-kinaze | |
| JP2006509749A5 (enExample) | ||
| CY1107974T1 (el) | Παραγωγα κινολινης και κιναζολινης εχοντα συναφεια προς τους υποδοχεις τυπου 5ht1 | |
| HRP20131139T1 (hr) | Novi supstituirani imidazokinolini | |
| JP2018058822A5 (enExample) | ||
| CY1114803T1 (el) | Παραγωγα πυριμιδινο σουλφοναμιδιου ως ρυθμιστες υποδοχεων χημειοκινης | |
| CN102317257A (zh) | 制备不对称双(缩氨基硫脲)的方法 |